Checkup Report

PO No :PO2090973467-964
Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Age/Gender : 23/Male Registration Date : 07-Feb-24 03:59 PM
Patient ID : MGP368199 Collection Date : 07/Feb/2024 10:36AM
Barcode ID/Order ID : D7452851 / 8929409 Sample Receive Date : 07/Feb/2024 04:57PM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA Report Date : 07/Feb/2024 07:12PM
HAEMATOLOGY
TCS WELLNESS PACKAGE PATHOLOGY CAMP
Test Name Result Unit Bio. Ref. Interval Method
Glycosylated Hemoglobin (HbA1c) 5.5 % 4 - 5.6 HPLC (NGSP certified)

Estimated average glucose (eAG) 111.15 mg/dL Calculated
Comment:
Interpretation: HbA1c%
≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes
Adapted from American Diabetes Association.
Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.
Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.
Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.
• HPLC - High performance liquid chromatography
Scan for
This test has been performed at digital copy
TATA 1MG PUNE
Address: Teerth Business Center, Ground Floor,
Unit No 1, Sub-Divided Plot No EL-15, Bhosari
MIDC, Pune - 411026
Page 1 of 16
PO No :PO2090973467-964

Sample Type : EDTA Report Date : 07/Feb/2024 06:42PM
HAEMATOLOGY
Complete Blood Count

Spectrophotometry:Cynide
Hemoglobin 14.7 g/dL 13.0 - 17.0
free SLS
RBC 4.96 mili/cu.mm 4.5 - 5.5 Electrical Impedence
HCT 45.1 % 40 - 50 RBC Pulse height detection
MCV 90.9 fL 83 - 101 RBC Pulse measurement
MCH 29.7 pg 27 - 32 Calculated
MCHC 32.7 g/dL 31.5 - 34.5 Calculated
RDW-CV 14.1 % 11.5-14 Calculated
Double hydrodynamic
Total Leucocyte Count 5.62 10^3/µI 4 - 10 sequential
system/Microscopy
Differential Leucocyte Count
Double hydrodynamic
Neutrophils 63 % 40-80 sequential
system/Microscopy
Double hydrodynamic
Lymphocytes 27 % 20-40 sequential
system/Microscopy
Double hydrodynamic
Monocytes 8 % 2-10 sequential
system/Microscopy
Double hydrodynamic
Eosinophils 1 % 1-6 sequential
system/Microscopy
Double hydrodynamic
Basophils 1 % 0-2 sequential
system/Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 3.54 10^3/µI 2-7 Calculated
Absolute Lymphocyte Count 1.52 10^3/µI 1.0 - 3.0 Calculated
Absolute Monocyte Count 0.45 10^3/µI 0.2 - 1 Calculated
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 2 of 16
PO No :PO2090973467-964

HAEMATOLOGY
Absolute Eosinophil Count 0.06 10^3/µI 0.02 - 0.5 Calculated
Absolute Basophil Count 0.06 10^3/µI 0.02 - 0.1 Calculated
Electrical Impedence/
Platelet Count 287 10^3/µI 150-410
Microscopy
MPV 9.5 fL 7.5-12 Calculated
PDW 19 fL 11-22 Calculated
Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts
are additionally being reported as absolute numbers of each cell in per unit volume of blood.
Erythrocyte Sedimentation Rate

Erythrocyte Sedimentation Rate 5 mm/hr 0-10 Modified Westergren
Comment:
ESR provides an index of progress of the disease and is widely used as an indicator of inflammation, infection, trauma, or
malignant diseases. Changes are more significant than a single abnormal test
It is specifically indicated to monitor the course or response to the treatment of diseases like rheumatoid arthritis,
tuberculosis bacterial endocarditis ,acute rheumatic fever ,Hodgkins disease,temporal arthritis , and systemic lupus
erythematosis; and to diagnose and monitor giant cell arteritis and polymyalgia rheumatica.
An elevated ESR may also be associated with many other conditions, including autoimmune disease, anemia,
infection,malignancy,pregnancy, multiple myeloma, menstruation, and hypothyroidism.
Although a normal ESR cannot be taken to exclude the presence of organic disease, its rate is dependent on various
physiologic and pathologic factors.
The most important component influencing ESR is the composition of plasma. High level of C-Reactive Protein, fibrinogen,
haptoglobin, alpha-1antitrypsin, ceruloplasmin and immunoglobulins causes the elevation of Erythrocyte Sedimentation
Rate.
Drugs that may cause increase ESR levels include: dextran, methyldopa, oral contraceptives, penicillamine, procainamide,
theophylline, and Vitamin A. Drugs that may cause decrease levels include: aspirin, cortisone, and quinine
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 3 of 16
PO No :PO2090973467-964

HAEMATOLOGY
"Test conducted on Whole Blood - EDTA "
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 4 of 16
PO No :PO2090973467-964

Sample Type : Fluoride Plasma F Report Date : 07/Feb/2024 06:42PM
BIOCHEMISTRY
Glucose - Fasting
Glucose - Fasting 92 mg/dL 70-99 Hexokinase/ G-6-PDH
Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes
Reference : American Diabetes Association
Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes
Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
Less than 7%
HbA1c
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 5 of 16
PO No :PO2090973467-964

Sample Type : Serum Report Date : 07/Feb/2024 07:57PM
BIOCHEMISTRY
Lipid Profile
Age>20 years : Desirable
<200,
Cholesterol - Total 187 mg/dL Enzymatic
Border Line 200 to 239,
High >240,
Normal: <150,
Borderline: 150 - 199, Glycerol Phosphate
Triglycerides 111 mg/dl
High:200-499, Oxidase
Very High>=500
Accelerator Selective
Cholesterol - HDL 54 mg/dl 40 - 60
Detergent
Desirable: <100
Above desirable: 100 -
129
Cholesterol - LDL 110 mg/dl Borderline high : 130 - Calculated
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 22 mg/dl 10 - 30 Calculated
Desirable : 3.5-4.5
Cholesterol : HDL Cholesterol 3.4 Ratio Calculated
High Risk : >5
Desirable : 2.5-3.0
LDL : HDL Cholesterol 2.03 Ratio Calculated
High risk : >3.5
Desirable:< 130,
Above Desirable:130 -
159,
Non HDL Cholesterol 133 mg/dl Borderline High:160 - Calculated
189,
High:190 - 219,
Very High: >= 220
Comment:
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 6 of 16
PO No :PO2090973467-964

BIOCHEMISTRY
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-
Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC
New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months
•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 7 of 16
PO No :PO2090973467-964

BIOCHEMISTRY
Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 8 of 16
PO No :PO2090973467-964

BIOCHEMISTRY
Liver Function Test

Bilirubin-Total 0.91 mg/dL 0.2-1.2 Diazonium Salt
Bilirubin-Direct 0.26 mg/dL 0.0-0.5 Diazo Reaction
Bilirubin-Indirect 0.65 mg/dL 0 - 0.8 Calculated
Protein, Total 8.28 g/dL 6.4 - 8.3 Biuret, End Point
Albumin 5.36 g/dL 3.5-5.0 Bromcresol Green
Globulin 2.9 g/dl 1.8 - 3.6 Calculated
A/G Ratio 1.84 Ratio Calculated
Aspartate Transaminase (SGOT) 44 U/L 11 - 34 NADH (Without P-5-P)
Alanine Transaminase (SGPT) 22 U/L 0-45 NADH (Without P-5-P)
SGOT/SGPT 2.00 Ratio Calculated
Para-Nitrophenyl
Alkaline Phosphatase 129 U/L 40-150
Phosphate
Gamma Glutamyltransferase (GGT) 9 U/L 12 - 55 L-G-G-3-C-4-N Substrate
Comment:
•LFTS are based upon measurements of substances released from damaged hepatic cells into the blood that gives idea of the
Existence, Extent and Type of Liver damage. - Acute Hepatocellular damage: ALT & AST levels are sensitive index of
hepatocellular damage - Obstruction to the biliary tract,Cholestasis and blockage of bile flow:1) Serum Total Bilirubin
concentration 2) Serum Alkaline Phosphatase (ALP) activity 3) Gamma Glutamyl Transpeptidase (GGTP) 4) 5`-Nucleotidase -
Chronic liver disease: Serum Albumin concentration
•Bilirubin results from the enzymatic breakdown of heme. Jaundice is a yellowish discoloration of the skin and mucous
membranes caused by hyperbilirubinemia.
•Pre-hepatic or hemolytic jaundice - Abnormal red cells, antibodies,drugs and toxins,Hemoglobinopathies, Gilbert’s syndrome,
Crigler-Najjar syndrome
•Hepatic or Hepatocellular jaundice-Viral hepatitis,toxic hepatitis, intrahepatic cholestasis
•Post-hepatic jaundice -Extrahepatic cholestasis, gallstones, tumors of the bile duct, carcinoma of pancreas
•In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT concentrations are
elevated even before the clinical signs and symptoms of disease appear.
•ALT is the more liver-specific enzyme and elevations of ALT activity persist longer than AST activity.
•Peak values of aminotransferase activity occur between the seventh and twelfth days. Activities then gradually decrease,
reaching normal activities by the third to fifth week. Peak activities bear no relationship to prognosis and may fall with worsening
of the patient's condition.
•Aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper
reference limit to four to five times higher, with an AST/ALT ratio greater than 1. The ratio's elevation can reflect the grade of
fibrosis in these patients. Slight or moderate elevations of both AST and ALT activities have been observed after administration
of various medications and chronic hepatic injury such as (1) hemochromatosis, (2) Wilson disease, (3) autoimmune hepatitis, (4)
primary biliary cirrhosis, (5) sclerosing cholangitis, and (6) a1-antitrypsin deficiency.
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 9 of 16
PO No :PO2090973467-964

BIOCHEMISTRY
•AST activity also is increased in acute myocardial infarction, progressive muscular dystrophy and dermatomyositis, reaching
concentrations up to eight times the upper reference limit.Slight to moderate AST elevations are noted in hemolytic disease.
•GGT is a sensitive indicator of the presence of hepatobiliary disease, being elevated in most subjects with liver disease
regardless of cause. Increased concentrations of the enzyme are also found in serum of subjects receiving anticonvulsant drugs,
such as phenytoin and phenobarbital.
Kidney Function Test.

Blood Urea Nitrogen 7 mg/dL 8-23 Urease
Urea 15.71 mg/dl 17.5 – 49.22 Calculated
Creatinine 0.95 mg/dl 0.6-1.2 Kinetic Alkaline Picrate
Uric Acid 5.4 mg/dL 3.7 - 7.7 Uricase
Sodium 139 mmol/L 136 - 145 Indirect ISE
Potassium 3.93 mmol/L 3.5-5.1 Indirect ISE
Chloride 101.6 mmol/L 98 - 107 Indirect
BUN/Creatinine Ratio 7.7 Ratio 12:1 - 20:1 Calculated
Comment:
BUN is directly related to protein intake and nitrogen metabolism and inversely related to the rate of excretion of urea.Blood
urea nitrogen (BUN) levels reflect the balance between the production and excretion of urea. Increased levels are seen in renal
failure (acute or chronic), urinary tract obstruction, dehydration, shock, burns, CHF, GI bleeding, nephrotoxic drugs. Decreased
levels are seen in hepatic failure, nephrotic syndrome, cachexia (low-protein and high-carbohydrate diets).
Urea is a non-proteinous nitrogen compound formed in the liver from ammonia as an end product of protein metabolism. Urea
diffuses freely into extracellular and intracellular fluid and is ultimately excreted by the kidneys. Increased levels are found in
acute renal failure, chronic glomerulonephritis, congestive heart failure, decreased renal perfusion, diabetes, excessive protein
ingestion, gastrointestinal (GI) bleeding, hyperalimentation, hypovolemia, ketoacidosis, muscle wasting from starvation,
neoplasms, pyelonephritis, shock, urinary tract obstruction, nephrotoxic drugs. Decreased levels are seen in inadequate dietary
protein, low-protein/high-carbohydrate diet, malabsorption syndromes, pregnancy, severe liver disease, certain drugs.
Creatinine is catabolic product of creatinine phosphate, which is excreted by filtration through the glomerulus and by tubular
secretion. Creatinine clearance is an acceptable clinical measure of glomerular filtration rate (GFR). Increased levels are seen in
acute/chronic renal failure, urinary tract obstruction, hypothyroidism, nephrotoxic drugs, shock, dehydration, congestive heart
failure, diabetes. Decreased levels are found in muscular dystrophy.
BUN/Creatinine ratio (normally 12:1–20:1) is decreased in acute tubular necrosis, advanced liver disease, low protein intake,
and following hemodialysis. BUN/Creatinine ratio is increased in dehydration, GI bleeding, and increased catabolism.
Uric acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels are
seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout, renal disorders, increased breakdown of body cells
in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia, sickle cell
anemia, or heart failure, pre-eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood levels of
parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats, some seafood
and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate antidiuretic hormone (SIADH),
certain drugs.
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 10 of 16
PO No :PO2090973467-964

BIOCHEMISTRY
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 11 of 16
PO No :PO2090973467-964

Immunology
Thyroid Stimulating Hormone, Ultrasensitive

Thyroid Stimulating Hormone - Ultra
1.983 uIU/ml 0.35 – 4.94 CMIA
Sensitive
Comment:
Reference ranges for TSH (μIU/ml) [As per American thyroid

Pregnancy
Association]
1st
0.1-2.5
trimester
2nd
0.2-3.0
trimester
3rd
0.3-3.0
trimester
TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection
or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
For the diagnosis of hypothyroidism and hyperthyroidism, sole dependence on TSH should not be done and assay needs
to be interpreted with the clinical condition & other investigations.
Serum TSH level changes significantly in response to even minor changes in thyroid hormones.
Transient increase in TSH level or an abnormal TSH levels can be seen in various nonthyroidal diseases.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 12 of 16
PO No :PO2090973467-964

Immunology
TSH T3 T4 Interpretation
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low
Hypothyroidism
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 13 of 16
PO No :PO2090973467-964

Sample Type : Urine Report Date : 07/Feb/2024 07:57PM
CLINICAL PATHOLOGY
Urine Routine & Microscopy

Colour PALE YELLOW Pale Yellow Visual
Appearance CLEAR Clear Visual
Specific gravity 1.015 1.003 - 1.035 pKa change
pH 6.5 4.6-8.0 Double Indicator
Glucose Negative Negative GOD-POD
Protein Negative Negative Protein- error principle
Ketones Negative Negative Nitroprusside
Blood Negative Negative Visual
Bilirubin Negative Negative Diazonium
Urobilinogen Normal Normal Azo Dye
Leucocyte Esterase Negative Negative Pyrrole
Nitrite Negative Negative Sulphanilamide Diazo
Pus cells 1-2 /hpf 0-5 Microscopy
Red Blood Cells NIL /hpf 0-2 Microscopy
Epithelial cells 1-2 /hpf Few Microscopy
Casts Nil /hpf Nil Microscopy
Crystals Nil Nil Microscopy
Yeast Nil Nil Microscopy
Bacteria Nil Nil Microscopy
Comment:
•Note: Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile
container is recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum,
Avoid prolonged transit time & undue exposure to sunlight.
•During interpretation, points to be considered are Negative nitrite test does not exclude the urinary tract infections. Trace
proteinuria can be seen with many physiological conditions like prolonged recumbency, exercise, high protein diet. False positive
reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like activity by disinfectants, therapeutic
dyes, ascorbic acid and certain drugs.• Urine microscopy is done in centrifuged urine specimens
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 14 of 16
PO No :PO2090973467-964

Barcode ID/Order ID : z8929409 / 8929409 Sample Receive Date : 01/Jan/0001 12:01AM
Sample Type : Human Subject Report Date : 07/Feb/2024 04:08PM
CLINICAL WELLNESS
Blood Pressure (BP)

Blood Pressure 148/73 mm Hg Oscillometric
Comment:
Classification Systolic/Diastolic
Normal BP <130/80
High normal BP systolic BP of 130-139 mm Hg & diastolic of 80-89 mm Hg
High normal/hypertension BP > 140 mm Hg systolic and/or greater than 90 mm Hg diastolic
Hypertension BP of >160 mm Hg systolic and/or greater than 100 mm Hg diastolic
Reference: Hypertension, Ministry of Health & Family Welfare Government of India (2016).
This is measured by a Phlebotomist and the same has been entered.
Body Mass Index (BMI)

Height 182.80 cm
Weight 86 kg
Body Mass Index 25.62 kg/m2 Calculated
Comment:
BMI is defined as a person's weight in kilograms divided by the square of his height in meters (kg/m2).
World Health Organization (WHO) defines overweight and obesity as abnormal or excessive fat accumulation that
presents a risk to health.
Obesity classification according to Asia-Pacific guidelines:
Classification BMI
Under-weight <18.5
Normal 18.5 - 22.9
Overweight 23–24.9
Obese ≥25
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 15 of 16
PO No :PO2090973467-964

Barcode ID/Order ID : z8929409 / 8929409 Sample Receive Date : 01/Jan/0001 12:01AM
Sample Type : Human Subject Report Date : 07/Feb/2024 04:08PM
CLINICAL WELLNESS
Reference: Asia Pacific Guidelines.

This is calculated by a Phlebotomist and the same has been entered.
*** End Of Report ***

Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID cs.labs@1mg.com
Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.
Scan for
TATA 1MG PUNE
MIDC, Pune - 411026
Page 16 of 16
Ensuring accuracy IN every single report
Following a 3-step review process:
Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor
Have concerns regarding the report?

Reach out to our care team
care@1mg.com 1800-212-2323
Accurate Testing, Assured Quality: Diagnostics Precision
Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 100+ years
Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision
Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>
Introducing
EXPLORE NOW >
Information on specialty medicines, oncologists

Need Help? 1800-102-1618
in your city, diagnostic tests, PSPs & more
*Clinical & Laboratory Standards Institute T&C Apply

Checkup Report

Uploaded by

Copyright:

Available Formats

Checkup Report

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Checkup Report

Uploaded by

Copyright:

Available Formats

PO No :PO2090973467-964

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Glycosylated Hemoglobin (HbA1c) 5.5 % 4 - 5.6 HPLC (NGSP certified)

Adapted from American Diabetes Association.

• HPLC - High performance liquid chromatography

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Complete Blood Count

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Erythrocyte Sedimentation Rate

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

Reference : American Diabetes Association

Plasma Glucose Goals For people with Diabetes

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

New treatment goals by Lipid Association of India (2020)

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Liver Function Test

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Kidney Function Test.

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Thyroid Stimulating Hormone, Ultrasensitive

Reference ranges for TSH (μIU/ml) [As per American thyroid

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Urine Routine & Microscopy

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Blood Pressure (BP)

Body Mass Index (BMI)

Name : Mr.SHASHWAT PANDEY Client Name : TATA 1MG PUNE

Reference: Asia Pacific Guidelines.

*** End Of Report ***

Advanced systems & Experienced lab experts Each report undergoes

Have concerns regarding the report?

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Verified test procedures External assessments Trained phlebotomists

Claim FREE doctor consultation

Information on specialty medicines, oncologists

*Clinical & Laboratory Standards Institute T&C Apply

You might also like

* End Of Report *